| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2251 | 2015 |
| Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle, D Bloomfield, ... The Lancet Oncology 17 (8), 1047-1060, 2016 | 1224 | 2016 |
| Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle, D Bloomfield, ... The Lancet Oncology 17 (8), 1047-1060, 2016 | 1224 | 2016 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 386 | 2017 |
| Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of … A Wilkins, H Mossop, I Syndikus, V Khoo, D Bloomfield, C Parker, J Logue, ... The Lancet Oncology 16 (16), 1605-1616, 2015 | 162 | 2015 |
| Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study J Mateo, HH Cheng, H Beltran, D Dolling, W Xu, CC Pritchard, H Mossop, ... European urology 73 (5), 687-693, 2018 | 118 | 2018 |
| Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study R Perez-Lopez, J Mateo, H Mossop, MD Blackledge, DJ Collins, M Rata, ... Radiology 283 (1), 168-177, 2017 | 104 | 2017 |
| Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis P Dutta, W Funston, H Mossop, V Ryan, R Jones, R Forbes, S Sen, ... Thorax 74 (4), 346-353, 2019 | 61 | 2019 |
| Cognitive decline in older patients with non‐ST elevation acute coronary syndrome SZ Gu, B Beska, D Chan, D Neely, JA Batty, J Adams‐Hall, H Mossop, ... Journal of the American Heart Association 8 (4), e011218, 2019 | 52 | 2019 |
| Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial C Harding, H Mossop, T Homer, T Chadwick, W King, S Carnell, ... bmj 376, 2022 | 51 | 2022 |
| A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer J Murray, C Griffin, S Gulliford, I Syndikus, J Staffurth, M Panades, ... Radiotherapy and Oncology 142, 62-71, 2020 | 42 | 2020 |
| ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient … R Forbes, A Ali, A Abouhajar, C Brennand, H Brown, S Carnell, ... Trials 19, 1-19, 2018 | 35 | 2018 |
| Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial J Murray, S Gulliford, C Griffin, A Wilkins, I Syndikus, J Staffurth, ... Clinical and Translational Radiation Oncology 21, 77-84, 2020 | 28 | 2020 |
| Antitumour activity of the PARP inhibitor olaparib in unselected sporadic castration-resistant prostate cancer (CRPC) in the TOPARP trial J Mateo, E Hall, S Sandhu, AG Omlin, S Miranda, S Carreira, J Goodall, ... Annals of Oncology 25, v1, 2014 | 18 | 2014 |
| Brief alcohol intervention for risky drinking in young people aged 14–15 years in secondary schools: the SIPS JR-HIGH RCT EL Giles, GJ McGeechan, S Coulton, P Deluca, C Drummond, D Howel, ... | 14 | 2019 |
| 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from … D Dearnaley, I Syndikus, H Mossop, A Birtle, D Bloomfield, C Cruickshank, ... | 14 | 2015 |
| Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016). DP Dearnaley, I Syndikus, H Mossop, AJ Birtle, DJ Bloomfield, ... Journal of Clinical Oncology 34 (2_suppl), 2-2, 2016 | 11 | 2016 |
| Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT C Harding, T Chadwick, T Homer, J Lecouturier, H Mossop, S Carnell, ... National Institute for Health and Care Research, 2022 | 9 | 2022 |
| The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of … S Ursprung, H Mossop, FA Gallagher, E Sala, R Skells, JAN Sipple, ... BMC cancer 21, 1-11, 2021 | 6 | 2021 |
| The association between vitamin D status and clinical events in high-risk older patients with non-ST elevation acute coronary syndrome undergoing invasive management B Beska, D Chan, S Gu, W Qiu, H Mossop, D Neely, V Kunadian Plos one 14 (6), e0217476, 2019 | 6 | 2019 |
